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Abstract 
The goal of the STAR Sexually Transmitted Infection Clinical Trial Group (STI CTG) 
Programmatic meeting on STIs in Pregnancy and Reproductive Health in April 2018 was to 
review the latest research and develop recommendations to improve prevention and management 
of STIs during pregnancy. Experts from academia, government, non-profit and industry 
discussed the burden of STIs during pregnancy, the impact of STIs on adverse pregnancy and 
birth outcomes, interventions that work to reduce STIs in pregnancy, and the evidence, policy, 
and technology needed to improve STI care during pregnancy. Key points of the meeting are as 
follows: (i)  Alternative treatments and therapies for use during pregnancy are needed; (ii) 
Further research into the relationship between the vaginal microbiome and STIs during 
pregnancy should be supported; (iii) More research to determine whether STI tests function 
equally well in pregnant as non-pregnant women is needed; (iv) Development of new lower cost, 
rapid point-of-care testing assays could allow for expanded STI screening globally; (v) Policies 
should be implemented that create standard screening and treatment practices globally; (vi) 
Federal funding should be increased for STI testing and treatment initiatives supported by the 
Centers for Disease Control and Prevention (CDC), the Centers of Excellence in STI Treatment, 
public STD clinics, and the President’s Emergency Plan for AIDS Relief (PEPFAR).  
Short Summary 
The STAR STI CTG programmatic meeting reviewed the latest research on STIs in pregnancy, 
and developed recommendations related to evidence, policy, and technology needed to improve 
STI care during pregnancy. 
Key words 
Sexually transmitted infections, pregnancy 
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Introduction 
STAR Sexually Transmitted Infection Clinical Trial Group (STI CTG) Programmatic 
meeting 
The goal of the STI CTG Programmatic meeting on STIs in Pregnancy and Reproductive 
Health was to review the latest research and develop recommendations to improve prevention 
and management of STIs during pregnancy. Experts from academia, government, non-profit and 
industry discussed the burden of STIs during pregnancy, the impact of STIs on adverse 
pregnancy and birth outcomes, interventions that work to reduce STIs in pregnancy, and the 
evidence, policy, and technology needed to improve STI care during pregnancy. 
Curable Sexually Transmitted Infections are Common 
Sexually Transmitted Infections (STIs) are common globally and disproportionately 
affect women and pose a large public health burden. In 2012,  there were 6 million new cases of 
syphilis, 78 million Neisseria gonorrhoeae (NG),131 million Chlamydia trachomatis (CT), and 
143 Trichomonas vaginalis (TV) infections globally.
[1]
 A recent systematic review found that the 
prevalence of curable STIs was particularly high among pregnant women in low- and middle-
income countries.
[2]
 TV prevalence was highest in Southern Africa (24.6%) followed by Asia 
(13.6%); syphilis prevalence (7.2%) was highest in East Africa; NG prevalance (4.6%) was 
highest in Southern Africa; and CT prevalence was  very high in Latin America (11.2%).
[2]
  
Untreated STIs are associated with adverse pregnancy and neonatal outcomes 
Curable STIs are associated with maternal morbidity,
[3]
 preterm birth, low birth weight, 
and stillbirth.
[4-6]
 Preterm birth is the leading cause of under-five mortality globally.
[7]
 A World 
Health Organization (WHO)-led study in 2013 found that prematurity and its associated 
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complications were the largest contributor to mortality in children globally accounting for 1 
million of the 6 million under-five deaths.
[8]
 According to the March of Dimes, in the United 
States, the rate of preterm birth increased to 1 in 10 babies (9.9% of live births), and the rate is 
highest among black infants (13.4%).
[9]
 In addition, there are around 2.6 million stillbirths per 
year of which 7% to 30% are caused by STIs or other infections.
[10-12]
 
About 50% of untreated maternal CT and NG infections are transmitted to the neonate 
during birth,
[13]
 which can cause eye and lower respiratory tract infections.
[14]
 Gonococcal eye 
infections can result in corneal damage and blindness if untreated.
[15]
 Pneumonia due to CT 
develops in 10%-20% of infants born to women with untreated CT infection.
[16]
 Curable STIs are 
also associated with increased mother-to-child transmission of HIV.
[17]
 
Antenatal STIs are often sub optimally diagnosed and treated 
Despite the large burden and risk to maternal and infant health posed by STIs, in most 
countries, routine antenatal testing for CT, NG, and TV infections is not offered.
[18]
 In 2015, only 
14 countries had policies recommending that pregnant women be tested for CT and/or NG 
infections.
[18]
 In the United States (US), the Centers for Disease Control and Prevention (CDC) 
recommends CT testing for all pregnant women and NG testing for pregnant women who are at 
increased risk or who live in areas where NG is highly prevalent.
[19]
 Diagnostic testing for TV is 
recommended for pregnant women seeking care for vaginal discharge and should be considered 
in high-prevalence settings.
[19]
  
Countries without STI testing guidelines rely on an approach called syndromic 
management,
[20]
 which uses algorithms to manage patients with specific STI syndromes (e.g. 
vaginal discharge syndrome) based on patient symptoms, clinical signs and select risk factors.
[21]
 
Patients are then treated with standardized drug regimens for the possible causes of their 
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syndromes, without testing for the etiologic organism. Syndromic management has a number of 
benefits, including timely treatment at the point-of-care, and no requirement for laboratory 
resources. While the syndromic approach has high sensitivity for symptomatic persons, because 
most STIs are asymptomatic the approach fails to detect the large majority of pregnant women 
with infection.
[21, 22]
 The syndromic approach also lacks specificity, potentially unnecessarily 
exposing pregnant women to antibiotics and undermining antimicrobial stewardship.
[21, 22]
 A 
recent systematic review and meta-analysis of the performance of abnormal vaginal discharge 
flowcharts used for syndromic management found that summary diagnostic performance 
estimates were consistently low for all flowcharts, regardless of whether risk assessments or 
clinical examinations were included.
[23]
 The authors recommended that future WHO guidelines 
exclude syndromic management of abnormal vaginal discharge to detect cervical infection.
[23]
 
Currently, the WHO is in the process of revising its STI care guidelines. 
 
Although antenatal syphilis testing is recommended by the WHO and available in most 
countries, there continues to be challenges related to uptake. Globally, only a few countries have 
reached at least 90% coverage during first antenatal care visits and in 26 countries, less than 50% 
of antenatal care attendees are tested for syphilis (data unavailable from the US).
[24]
 Further, in 
the US where syphilis testing is a routine part of antenatal care, the number of congenital syphilis 
cases more than doubled between 2013 and 2017.
[25]
  
Rates of partner notification and treatment are low 
Partner notification is a process where sex partners of an index patient with an STI are 
identified, notified about their exposure, counselled, and treated.
[26]
 Treating partners reduces the 
likelihood of re-infecting the index patient,
[27]
 and decreases the burden of infection in 
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communities because the partners are often asymptomatic and otherwise unlikely to access 
care.
[28]
.  
Partner notification is governed by country-specific policies related to the control of 
communicable diseases.
[29]
 There is variation between countries; however, voluntary, patient-
based partner notification is the most common method globally.
[30, 31]
 Some countries allow for 
expedited partner therapy, which is the clinical practice of treating partners by providing 
medications to the index patient to give to a partner prior to an examination of the partner by a 
healthcare provider.
[32]
 Regardless of the strategy, partner notification is often low.
[33, 34]
 A 
systematic review of partner notification strategies in low- and middle-income countries found 
that the median proportion of sex partners notified in the 39 included studies was 54%.
[33]
 
Limited prior research has found that although pregnant women report higher rates of 
willingness to notify partners about an STI, this willingness does not always translate to higher 
rates of partners receiving treatment.
[33, 35]
  
Innovations may allow for improvements in STI testing, treatment, and prevention of 
reinfection 
Innovations in diagnostics may allow for the expansion of STI testing and improved 
management, particularly in low resource settings. Characteristics of new diagnostics include:  
easy to use, multiplex, and patient-collected samples.
[36]
 Additionally, STI diagnostic platforms 
are available that allow for patient diagnoses outside of clinical laboratories, have high 
sensitivity and specificity, and allow for rapid results (while the patient is still present).
[36]
 Rapid 
tests have the potential to dramatically reduce the time between testing, results, and treatment, 
which may increase the likelihood of STI treatment and ultimately improve cure rates.
[37]
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Several studies have found that routine, rapid, antenatal syphilis, CT, NG, and TV testing 
is acceptable, feasible, and cost-effective in certain circumstances. A recent short report found 
that uptake of antenatal STI testing was high across diverse settings ranging from 85.2% in the 
Democratic Republic of Congo to 99.3% in Vietnam. Further, treatment was also high and 
ranged from 91.7% to 100%.
[38]
 
In terms of cost-effectiveness, two recent studies evaluated testing pregnant women for 
chlamydial infections.
[39, 40]
 An Australian study looked at antenatal CT testing among women 
aged 16-25 years compared to women with no testing and found that testing cost $183 more per 
case detected than no testing.
[39]
 A US-based study comparing testing all pregnant women to no 
testing found that testing cost $19 more per case detected and treated.
[40]
 Although both studies 
found that testing was more costly than no testing, when considering adverse outcomes averted 
due to testing and treatment (e.g. preterm birth and low birth weight infants averted) testing 
resulted in cost savings at higher CT prevalence rates (e.g. Australia study threshold was 11% 
and US-study was 16.9%). Those studies had several limitations that may change the cost-
effectiveness ratio: only short-term outcomes and costs were assessed and benefits among 
partners were not examined. 
Antenatal syphilis testing has been found to be cost effective even in low prevalence 
settings and cost-saving after adjusting for averted medical care.
[41]
 However, questions remain 
about how to increase testing and treatment uptake. Several studies have looked at the issue of 
whether to use point-of-care versus centralized testing and have different results depending on 
the setting. A study in Mongolia found that point-of-care testing reduced rates of congenital 
syphilis compared to centralized testing.
[42]
 However, a study in South Africa found that point-
of-care testing did not increase treatment rates, but reduced the time to treatment.
[42]
 A study in 
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Zambia found that more women were tested using a point-of-care strategy compared to 
centralized testing, but treatment rates were not different.
[43]
 In addition, utilizing dual point-of-
care testing for syphilis and HIV infection has the potential to simplify training and procurement 
and reduce burdens on laboratories and patients. Dual testing  has been shown to be cost-
effective.
[44]
 
Pathogenesis of Adverse Maternal, Pregnancy & Neonatal Outcomes 
Mechanisms for Adverse Impact of Perinatal Infectious on Pregnancy Outcomes 
STIs are associated with increased inflammation,
[45]
 which may play a role in adverse 
perinatal and infant outcomes. Intrauterine infection/inflammation is associated with about 40% 
of preterm deliveries.
[46]
 An animal model where intrauterine inflammation was induced by 
injection of agonists into amniotic fluid,
[47]
 found that the cytokine interleukin-1 (IL1) is a 
critical mediator in perinatal inflammation. This result suggests that IL1 is a potential therapeutic 
target. A cord blood study conducted in Cincinnati found that intrauterine inflammation was 
associated with adverse pulmonary outcomes at 6 to 12 months in moderate/late preterm 
infants.
[48]
 Adverse outcomes associated with low lung function at birth can continue well into 
the fourth decade of life.
[49, 50]
 
Mycoplasma genitalium in Pregnancy  
In women M. genitalium is common and associated with adverse outcomes of pregnancy, 
including preterm birth, and is a contributor to perinatal mortality and morbidity.
[51, 52]
  A multi-
site study in the United States of 1,139 women at risk for STIs found the prevalence of M. 
genitalium was 20.5%.
[53]
 Another study in the United States among pregnant women receiving 
routine antenatal care demonstrated a prevalence of 8.4%.   Research is needed to understand if 
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M. genitalium infects the placenta, chorion and/or amnion, and/or causes inflammation and 
sequelae such as neonatal conjunctivitis or respiratory distress. 
[51, 52]
  
Additional research is also needed to better understand the impact and optimal regimen of 
M. genitalium treatment. Treatments for M. genitalium have been hampered by antibiotic 
resistance and some treatments, such as doxycycline, moxifloxacin and clarithromycin, are 
contraindicated or lack sufficient human data in pregnancy. Azithromycin is a treatment option; 
however, resistance is increasing and it is an FDA pregnancy category B drug. Lefamulin may be 
a future treatment option as Phase 2 clinical trials of Lefamulin
[54]
 have provided some safety 
data in pregnancy.  
Vaginal Microbiome and Pregnancy 
Research of the human microbiome and its diversity has helped to elucidate its role in 
health and human disease.
[55]
 A normal vaginal microbiome is  primarily dominated by 
Lactobacillus species.
[56]
 Lactobacillus species produce lactic acid to maintain a normal vaginal 
pH and may play a role in preventing urogenital diseases such as bacterial vaginosis (BV), 
vaginal yeast infections, and urinary tract infections as well as in acquiring or transmitting STIs. 
Hence, disruption or modulation of the normal vaginal microbiota may contribute to increased 
susceptibility to infectious disease and adverse outcomes.  
A study conducted by Ravel et al examined the vaginal microbiome species composition 
of 396 asymptomatic, reproductive aged, North American women.
[57]
  Investigators were able to 
subdivide vaginal microbiomes into five community state types (CST) including CST I: 
Lactobacillus crispatus, CST II: Lactobacillus gasseri, CST III: Lactobacillus iners, CST IV: 
Lactobacillus jensenii and CST V: Lactobacillus-poor.
[57]
 The proportion of CST varied by race 
(i.e., white, black, Hispanic and Asian) but not by age. It was determined that L. crispatus was 
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most associated with stable vaginal microbiota  and that an abnormal vaginal microbiome was 
associated with loss of lactic acid-producing lactobacilli, higher Nugent scores (used in BV 
diagnosis; associated with preterm birth), higher proportion of Gardnerella vaginalis, and the 
presence of strict anaerobes.   
A longitudinal analysis of the vaginal microbiome in pregnancy was conducted by 
collecting lateral vaginal wall swabs during the first, second and third trimester from 100 
pregnant women in Belgium.
[58]
  From that study, 77 women (77%) were found to have normal 
or Lactobacillus-dominated vaginal microflora during the first trimester. Of these 77 women, 64 
(83.1%) maintained normal vaginal microbiota throughout their pregnancy, whereas 13 women 
(16.9%) converted to abnormal vaginal microbiota during the second or third trimester. Women 
with L. gasseri and/or L. iners were ten times (RR = 9.49, 95% CI 1.30 – 69.40; p=0.009) more 
significantly likely to convert from normal to abnormal vaginal microbiota during pregnancy 
compared to women with L. crispatus-dominated vaginal microbiota. Overall, it was concluded 
that the species composition affects the stability of the vaginal microbiome in pregnancy.  
Romero et al extended these findings by conducting a retrospective case-
controllongitudinal study of 22 healthy, pregnant women (delivering at term) and 32 healthy, 
non-pregnant women to characterize the vaginal microbiota during normal human pregnancy. 
They found that pregnant women had a higher abundance of of L. crispatus, L. gasseri, and L. 
jensenii and a lower abundance of 22 other phylotypes (many associated with CST IV-A and IV-
B) over time compared to non-pregnant women.
[59]
 In this study, CST IV-B or CST IV-A were 
characterized by a high relative abundance of species of the genus Atopobium as well as 
Prevotella, Sneathia, Gardnerella, Ruminococcaceae, Parvimonas, Mobiluncus and other taxa 
previously shown to be associated with BV. The authors of this study hypothesized that 
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maintaining a CST dominated by Lactobacillus spp. during pregnancy may confer a protective 
role against ascending infection of the genital tract during this time.   
These same investigators subsequently conducted a nested case-control study of pregnant 
women delivering at term (controls) versus those with spontaneous preterm delivery before 34 
weeks of gestation (cases) to determine if any significant differences could be found within the 
vaginal microbiome of women with pre-term vs. term delivery.
[60]
 Interestingly, the authors 
found no difference in the relative abundance of bacterial taxa in the vaginal microbiome 
between women with spontaneous preterm delivery and those who delivered at term. In addition, 
no differences in the frequency of vaginal CSTs between women with spontaneous preterm 
delivery and those who delivered at term. However, the results of this study were limited by a 
small sample size (i.e. only 18 patients with preterm delivery were included). In contrast, a 
prospective case-control study 
[61]
 of 49 pregnant women by DiGiulio found that prevalence of a 
Lactobacillus-poor vaginal community state type (CST 4) with high levels of Gardnerella or 
Ureaplasma was inversely correlated with gestational age at delivery (P = 0.0039).  The study 
also found that most women experienced a post-delivery disturbance in vaginal microbiota 
characterized by a decrease in Lactobacillus spp. and an increase in diverse anaerobes such as 
Peptoniphilus, Prevotella, and Anaerococcus spp.  This disturbance was unrelated to gestational 
age at delivery and persisted for up to 1 year after delivery. Reasons for the discordance between 
the results of this study and that of Romeo et al
[59]
 are likely multi-factorial including differences 
in the racial composition of the study cohorts, the timeframe of pre-term birth cases, and whether 
or not pre-term birth was spontaneous or non-spontaneous.
[61]
 Identifying  signatures/markers in 
the vaginal microbiota for predicting premature birth should be a focus of future research efforts.  
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Hyman et al have also assessed the diversity of the vaginal microbiome and its potential 
association with preterm birth in a prospective study of 88 pregnant women.
[62]
 L. crispatus was 
found to be highly abundant in the vaginal microbiome of Caucasian women while L. iners was 
highly abundant in African American and Hispanic women. Species diversity was greatest 
among African American women. The investigators found that diversity of the vaginal 
microbiome correlated with preterm birth and that race and ethnicity were important variables. 
Of the 19% of women with preterm birth (among the 88 women followed), 15% were Hispanic, 
18% were Caucasian, 25% were African American, and 25% were Asian.  
Overall, studies conducted to-date have revealed that the vaginal microbiome becomes 
less diverse and more stable during pregnancy and is largely dominated by Lactobacillus spp.
[59]
 
Data collected thus far suggest that the distribution of predominate vaginal CSTs during 
pregnancy varies by population, race, and ethnicity. It is not clear, however, what precipitates the 
shift from normal vaginal microbiota to abnormal vaginal microbiota . Whether such shifts in 
CSTs are a result of (i) the initial loss of vaginal lactobacilli, potentially caused by behavioral 
activities or other inciting events, (ii) sexual acquisition of a sexually transmitted pathogen that 
leads to complex changes in the vaginal microbiota or (iii) sexual acquisition of a polymicrobial 
consortium of micro-organisms is not clear.
[63]
 Further, the influence of sexual activities on the 
vaginal microbiota during pregnancy is not well defined.  
 
Vaginal Microbiome: Next Steps 
Much previous research related to the vaginal microbiome are limited by small sample 
sizes, and thus more research is needed. Further, research is needed to identify biomarkers 
associated with adverse pregnancy outcomes in both uninfected women and those infected with 
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STIs. Future cohort or banked sample studies will assess the species composition and regulation 
of the vaginal microbiome during pregnancy, and will examine the severity of STIs and 
pregnancy outcomes. Those studies are necessary to define the relevant endpoints and clinical 
outcomes in both pregnant and non-pregnant populations and examine variables such as race and 
sexual behavior. However, the lack of standardization with regard to vaginal microbiome testing 
platforms is a challenge that must first be addressed.
[63, 64]
 From that work, greater insight will be 
gained into STI etiology in pregnancy and biomarkers/predictors of various outcomes including 
preterm labor, membrane rupturing, still birth, early neonatal infectiouns and immune 
modulation. A number of clinical studies of vaginal probiotic supplementation with or without 
antimicrobials to improve vaginal dysbiosis or pregnancy outcomes are either underway or 
planned 
(https://clinicaltrials.gov/ct2/results?cond=&term=vaginal+probiotics&cntry=&state=&city=&di
st=) however vaginal probiotics are not currently recommended for vaginal dysbiosis in the CDC 
STD Treatment Guidelines.
[65]
 
Gaps and Clinical Issues in STI Prevention/Control 
Gaps in Prevention and Control of Congenital Syphilis 
Congenital syphilis cases are on the rise in the United States and in 2017 there were 918 
cases of congenital syphilis reported to the CDC. To address the rise in syphilis among pregnant 
women as well as men who have sex with men, the CDC issued a call to action
[66]
 for 
communities impacted by congenital syphilis  and other groups who have a role to reduce the 
burden of infection through research, treatment, and outreach. The CDC call to action 
encourages key stakeholders to: Create new tools to detect and treat syphilis and increase testing 
in order to control the further spread of syphilis, and to improve electronic medical records in 
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order to improve patient outcomes. In the call to action, the CDC also published a list of 
stakeholders that they believe need to take action. The CDC Division of Sexually Transmitted 
Disease (STD) Prevention (DSTDP) is undertaking a number of activities including, ongoing 
epidemiological research and analysis of surveillance data; convening local, state and national 
partners to foster connectivity and the promotion of  best practices; developing and applying care 
cascade and case review board practices to support in-depth analysis of medical care gaps and 
congenital syphilis rates.  
There are also state-level activities taking place. In 2017, the CDC awarded nine state and 
local health department STD programs a total of $4 million in order to enhance their congenital 
syphilis responses. The goals of that program were to make sustainable improvements to 
congenital syphilis related activities, strengthen prevention through prospective information 
gathering and interventions and retrospective activities to identify opportunities for change. Key 
activities included improving data collection of maternal and fetal epidemiologic and clinical risk 
factors; improved ascertainment of pregnancy status among female syphilis cases; strengthening 
congenital syphilis morbidity and mortality case review boards; matching syphilis surveillance 
data with vital statistics; and strengthening partnerships with maternal and child health programs 
and healthcare providers.   
In addition to resources provided directly by the CDC, funding is provided to support the 
National Network of STD Clinical Prevention Training Centers (NNPTC) to assist clinicians in 
the United States with the skills, knowledge and experience that they need to address and prevent 
STDs in their patients. The NNPTC provides regional based in-person clinical training as well as 
on-line resources including the STD clinical consultation network (CCN (www.STDCCN.org)) 
and the national STD curriculum that can be found at www.std.uw.edu. The curriculum includes 
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seven self-study modules with an individual progress tracker and provides free continuing 
education credits.  
Clinical Issues related to STIs and Pregnancy  
 Bacterial and viral STIs have an influence on pregnancy outcomes and pregnancy can 
modify the manifestation of some STIs. Thus, the timeliness of treatment during pregnancy is 
essential to avoid adverse outcomes.   
 Neonatal Herpes Simplex Virus (HSV) infection occurs in anywhere from 1 in 3,000 to 1 
in 10,000 pregnancies.
[67]
 An estimated 1,500 cases of neonatal HSV occur each year in the US 
and more than 100 babies die from neonatal herpes.
[67]
 Neonatal HSV can be caused by either 
HSV-1 or HSV-2; however, two-thirds of cases in the Americas are caused by HSV-1.
[67]
  
Worldwide neonatal HSV occurs in 10.3 per 100,000 live births and two-thirds of cases are 
caused by HSV-2.
[67]
  Among pregnant women in the US, HSV-2 has a seroprevalence between 
20% and 30% and HSV-1 has a seroprevalence of 60%.
[68]
  Approximately 10% of HSV-2 
seronegative women have a seropositive partner, while up to one-third of women of childbearing 
age are seronegative for HSV-1 and HSV-2 and 3.7% of those women will acquire either virus 
during pregnancy.
[68]
  
 Eighty-five percent of babies who develop neonatal HSV acquire the disease during labor 
and delivery.
[69]
  Most transmissions occur during asymptomatic shedding and most women have 
no signs or symptoms. A study conducted on women giving birth found that in recurrent HSV 
infection the risk of mother-to-child transmission (MTCT) is quite low and that the risk of 
MTCT is highest during the first episode of genital HSV.
[69]
 While most benign forms of 
neonatal HSV occur in the skin, eyes or mouth, 1 in 4 neonates will have a life-threatening 
disseminated infection.
[70]
 Incorporation of antiviral drugs during pregnancy, especially during 
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the third trimester, can reduce the clinical occurrence of maternal HSV at the time of delivery by 
75%.
[71]
  Antiviral suppression can also reduce the number of cesarean deliveries by 40% and 
can reduce viral shedding at the time of delivery by 90%.
[71]
 There is insufficient evidence about 
whether antiviral suppression late in the third trimester can prevent neonatal herpes.  Other 
strategies to reduce neonatal HSV include routine screening and better diagnostic tools to 
confirm whether a suspicious legion is herpes.  Rapid point-of-care tests for HSV shedding 
would be helpful in reducing cesarean deliveries and would allow neonatologists to implement 
early antiretroviral therapy in infants born to mothers with HSV shedding at the time of birth.  
 There are approximately 2 million cases of syphilis in pregnant women worldwide and 
syphilis is associated with adverse pregnancy outcomes.
[6]
  Over the last five years, there has 
been an 87% increase in congenital syphilis worldwide.
[25]
 Timely treatment is essential in 
preventing congenital syphilis, as over one-half of pregnancies in women with untreated syphilis 
will result in adverse outcomes.
[72]
 Implementation of point-of-care testing and/or rapid tests are 
essential in order to detect syphilis earlier in pregnancy and to reduce/prevent congenital syphilis 
worldwide.
[73, 74]
 In addition, standard of care treatment for pregnant women with syphilis is the 
same as the standard of care treatment for non-pregnant women. Penicillin is the recommended 
treatment to prevent MTCT of syphilis and for treating neonatal infection. Alternative treatments 
for syphilis can also be problematic; for instance, there is limited data about the use of 
ceftriaxone in pregnant women to prevent congenital syphilis.
[75]
 Additional barriers to treatment 
of syphilis especially in pregnant women include penicillin shortages and failure by insurers to 
cover fully penicillin for syphilis treatment.
[76]
 There are also concerns about the impact of the 
opioid epidemic on syphilis and individuals who are unable or unwilling to seek care.   
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 Neisseria gonorrhoeae (NG) infections during pregnancy increase the risk for preterm 
birth, premature rupture of membranes, intraamniontic infection, low birth weight, and 
postpartum endometritis.
[77-79]
 Screening pregnant women who are at risk for NG infections 
could help to reduce MTCT of both HIV infection and NG infection.
[17]
 Researching alternative 
treatments is also important as the only currently recommended regimen for NG in pregnancy is 
ceftriaxone and azithromycin and there are limited options for alternative regimens for patients 
with allergies or those with antibiotic resistance.
[19]
   
 Antenatal Chlamydia trachomatis infection is also associated with preterm birth, low 
birth weight, intrapartum fever and late postpartum endometritis.
[80]
  Alternative treatment 
regimens are also urgently needed especially for those with intolerance or allergies to current 
treatment regimens.  
 Trichomonas vaginalis infection is associated with vaginal and systemic immune 
activation as well as preterm delivery and low birth weight.
[81]
  However, questions remain about 
whether at-risk pregnant women should be screened for TV infection. For example, a previous 
study of screening and treating asymptomatic TV during pregnancy did not reduce preterm 
delivery.
[82]
  
 In summary, since STIs in pregnancy may have serious adverse consequences, timely 
diagnosis and treatment are important.  The data on some STIs in pregnancy are limited and 
dated.  There is a lack of data on co-morbidities.  Advances in diagnostics should be used to 
optimize screening for, and treatment of STIs in pregnancy to prevent maternal morbidity, 
adverse pregnancy outcome, and, transmission to the neonate.  Finally, effective anti-infective 
therapies are needed to address issues such as antimicrobial resistance and must be studied in 
pregnant women.
[83]
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Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) Biorepository   
 The mission of the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) is to 
reduce the burden of preterm birth and stillbirth by advancing collaborative research in order to 
identify, develop, and implement evidence-based solutions.
[84]
 The GAPPS Biorepository was 
created in 2009 and opened in 2012 through philanthropic support. The GAPPS Biorepository 
provides a unique and widely accessible international biobank with comprehensive maternal and 
newborn phenotypic data linked to high-quality tissue biospecimens at several timepoints from 
early pregnancy through childbirth and postpartum, which includes diverse populations and 
geographies. The GAPPS Biorepository model supports many types of research ranging from 
parturition to adverse pregnancy outcomes including origins of chronic disease, genetics/biology, 
pathophysiology, molecular etiology, epidemiology, diagnostics and biomarkers, translational 
science, healthcare delivery and new therapies/prevention solutions.  Participants are enrolled 
early in pregnancy with ultrasound dating of gestational age, and receive period follow up during 
each trimester of pregnancy, and at birth and during the postpartum period. Standardized clinical, 
nutritional and demographic data linked to biospecimens and pregnancy case records with 
standardized classification of complications and adverse outcomes are collected. The GAPPS 
Biorepository provides state of the art systems for the collection, preservation, managed access 
and quality assurance of robust standardized data for pregnancy and newborn cohorts that 
buildout and support a global network of biorepositories in order to enable data sharing and/or 
specimen transfer and accelerate research. In addition, efforts continue to develop new, 
harmonized international repositories for under-represented populations. To date, the GAPPS 
Biorepository has enrolled more than 4,500 women in Bangladesh, 3000 women in the US and 
1,500 women in Zambia.   
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 The GAPPS Biorepository program is designed to be self-sustainable, by addressing 
challenges to biobanking, including upfront collection costs, regulatory burdens, participant 
retention, supply chain, maintenance of technical equipment and data management, and 
anticipating needs to design relevant specimen/data collections. The GAPPS Biorepository 
provides many collaborative opportunities and a unique value proposition by improving 
efficiencies, shortening research throughput, and reducing research costs, while providing the 
potential for follow up study of children born to enrolled mothers and creating agnostic 
infrastructure for future clinical trials and emerging multi-discipline research that ultimately 
benefit public health.  
Clinical Research Priorities Moving Forward 
 Three main clinical research priorities were identified (Table 1). There is an urgent need 
to identify more STI treatments, especially for pregnant women. A starting point is with studies 
of drugs that are known to be safe and efficacious in non-pregnant adults. The use of animal 
models and/or conducting retrospective trials in countries where alternative therapies are used 
could provide useful preliminary data.  Cord blood studies and ex-vivo studies may serve as 
possible avenues to improve the treatment of STIs in pregnancy.  
 Adequate infrastructure, personnel capacity, and cost-effectiveness remain challenges to 
the implementation of routine STI screening in pregnant women. Point-of-care rapid diagnostic 
testing could provide solutions to some challenges, particularly in low- and middle-income 
settings, because they are easy to use and patients can collect their own samples. More evidence 
is needed demonstrating the feasibility of application, scale- up, and cost-effectiveness of STI 
screening during pregnancy, particularly studies that compare point-of-care versus off-site 
testing and multiple vs single STI testing.  
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 Finally, there is a need for greater understanding about the relationship between the 
vaginal microbiome and STI transmission and acquisition.  
Laboratory Priorities 
There are also four main laboratory priorities (Table 1). There is an urgent need to 
develop novel point-of-care rapid diagnostic tests that target pregnant women. Novel point-of-
care rapid diagnostic tests should be handheld, easy to operate, cost effective and should return 
results quickly so that patients may be quickly treated.  Development of such novel point-of-care 
tests could help reduce transmission of STIs and be used as a triage tool or confirmatory device 
to help reduce overtreatment. In order to reduce costs, improve the ability to detect and treat co-
morbidities, and improve maternal and perinatal outcomes new STI tests should be designed to 
be able to detect multiple pathogens. 
Studies have shown some promise related to the use of the vaginal microbiome as a 
predictor of pregnancy outcomes, however, markers have shown a very small impact in terms of 
public health. Larger studies are needed in order to validate before testing studies are 
implemented. Further, it is necessary to move from exploratory studies towards longitudinal 
studies. Finally, more research is needed in to the pathogenesis of intrauterine 
infection/inflammation and how vaginal dysbiosis can cause intrauterine infection/inflammation. 
Policy Priorities 
 In the US, the creation of an Office of STI Research at the National Institutes of Health 
(NIH) would allow for better integration of STI research policies and priorities, especially as 
relevant to  HIV research while working in conjunction with the Office of AIDS Research 
(OAR). Policies should be implemented that create and require the monitoring of standard 
antenatal care screening recommendations and treatment practices across the US. Given the 
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recent upsurge in STIs in the US, funding increases for the CDC’s STD prevention efforts and 
the Centers of Excellence in STI Treatment are needed. In the context of a congenital syphilis 
crisis, it would be useful to expand the Fetal and Infant Mortality Review to include congenital 
syphilis. Utilizing federal funding to expand the number and hours of local STD clinics could 
better serve communities at risk. Highlighting jurisdictions that are doing well with STI 
screening and treatment, especially during pregnancy, could incentivize improvements in care. 
Furthermore, PEPFAR supported initiatives should increase STI screening, testing and care 
programs and at least 20% of funding from PEPFAR and the Global Fund should be focused on 
STIs.  
 Routine STI screening during pregnancy should be included in the WHO guidelines. The 
WHO recently published antenatal care guidelines that include HIV, syphilis, urinary tract 
infection, malaria, and anemia screening, depending on the geographic location.
[85]
  If enough 
evidence is not available to do so, the WHO should convene a meeting including relevant experts 
to identify research gaps and plan a program to address those gaps. Providers and researchers 
also need to continue to request an integrated approach to antenatal and postnatal care inclusive 
of STI screening and treatment in policy and practice.  
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Table 1. Identified Clinical, Laboratory, and Policy Priorities To 
Address Sexually Transmitted Infections in Pregnancy.  
Clinical Research Priorities 
1. Alternative treatments for STIs during pregnancy 
2. Routine screening with point-of-care rapid diagnostic testing 
for STIs during pregnancy globally 
3. Further research into the vaginal microbiome 
Laboratory Priorities 
1. Assess STI test performance in pregnant vs. non-pregnant 
women 
2. Develop further point-of-care tests  
3. Develop microbial based biomarkers for adverse pregnancy 
outcomes 
4. Research in pathogenesis of intrauterine 
infection/inflammation and the link between vaginal dysbiosis 
and intrauterine infection/inflammation 
Policy Priorities 
1. Create Office of STI Research at the NIH. 
2. Increase national policies that create and require monitoring 
of standard antenatal care screening recommendations and 
treatment practices 
3. Include congenital syphilis in Infant Fetal and Infant Mortality 
Reviews  
4. Expand Federal funding for STD clinics to increase access 
5. Increase STI screening and treatment in PEPFAR-supported 
programs. 
6. Add STI screening and treatment as part of integrated 
antenatal care packages globally  
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